Characteristics & Business Summary
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I...
Income Statement Highlights
(¥ Million, except EPS/DPS in ¥)
| Fiscal Period | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|
| Net Sales | 3 | 15 | 5 | 0 | 1 |
| Operating Profit | -1,733 | -1,476 | -1,467 | -1,155 | -1,161 |
| Ordinary Profit | -1,739 | -1,482 | -1,474 | -1,159 | -1,148 |
| Net Profit | -1,720 | -1,484 | -1,486 | -1,168 | -1,151 |
| EPS | ¥-34 | ¥-27 | ¥-24 | ¥-17 | ¥-13 |
| DPS | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 |
Balance Sheet & Valuation Highlights
Total Assets
¥1B
Net Assets (Equity)
¥1B
Equity Ratio
80.6%
ROE (Return on Equity)
-127.4%
Cash & Equivalents
¥1B
Interest-Bearing Debt
¥0B
Capital Expenditure (CapEx)
¥0B
Depreciation & Amort.
—